Dr Th. Dhabali Singh, Managing Director, Babina Diagnostics, Imphal

The wide prevalence of certain infectious diseases in the Northeast and the neighbouring country of Myanmar challenges us with opportunities for expanding our diagnostics market, in particular, that of molecular diagnostics.

The molecular diagnostics market has been our keen area of interest in the past few years and, in our laboratory, this is one segment that has seen tremendous changes in the last few years. PCR and hybridization-based assays have been dominating this segment.

The growth of molecular diagnostics market is closely linked to the prevalence of chronic infections. Over the last two decades or so, Manipur and the entire Northeast region has witnessed increasing incidences of chronic infections like HIV, hepatitis B, and hepatitis C, including tuberculosis (TB). In fact, the prevalence of these diseases extends across the border into Myanmar.{mosimage}

Molecular diagnostics market continues to be dominated by virology tests and tuberculosis testing. For our molecular biology lab, we have recently acquired GeneXpert system from Cepheid. This is over and above the Roche's Cobas Taqman48, which we have been using since 2009 and Rotor-Gene Q PCR system from Qiagen. This way we have increased our menu of virology and tuberculosis tests.

We seriously believe that there is a huge untapped market in the neighboring country of Myanmar. We have been keeping a close watch on the emerging political developments there. Ours is already a trusted brand across the border and we are keen to exploit this to our advantage.

Our procurement plans for 2016 for other sections of our laboratory include Aperio Digital Scanner from Leica. This is for precise, high-resolution image capture of slide details for bright field, fluorescent, or FISH specimens.


10 Diagnostic Imaging Trends for 2018

Best of 2017 Medical

 

Digital version